Secrin M 1/500 XR
- This oral hypoglycemic preparation combines glimepiride and metformin.
- It supports the management of type 2 diabetes mellitus.
- The tablet serves as a complementary treatment alongside diet and exercise.
- It is particularly beneficial when monotherapy with glimepiride or metformin is inadequate.
- Glimepiride stimulates insulin release, while metformin improves insulin sensitivity and reduces hepatic glucose production.
- Careful dosage adjustments and regular monitoring are essential for optimal glycemic control and minimizing side effects.
Viglimet 50+500
- Viglimet combines Vildagliptin and Metformin Hydrochloride for improved glycemic control in type 2 diabetes.
- Enhances insulin secretion and reduces hepatic glucose production.
- Suitable for patients not adequately controlled on Metformin or Vildagliptin alone.
- Ensures safe and effective diabetes management with high standards of care and patient safety.
Viglimet 50+850
- Viglimet combines Vildagliptin and Metformin Hydrochloride for improved glycemic control in type 2 diabetes.
- Enhances insulin secretion and reduces hepatic glucose production.
- Suitable for patients not adequately controlled on Metformin or Vildagliptin alone.
- Ensures safe and effective diabetes management with high standards of care and patient safety.